Questions about COVID-19?

What Patients & Families Need to Know | New Visitor Policy | Guidance for Community Healthcare Providers

A photo of Michael Jordan.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Member, Division of Immunobiology

Professor, UC Department of Pediatrics

513-636-1773

513-803-1969

Board Certified

My Biography & Research

Clinical Interests

Histiocytic disorders: HLH and LCH

Research Interests

Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Langerhans Cell Histiocytosis, Autoimmune Liver Disease, Bone Marrow Transplantation, Cancer and Blood Diseases, Immunobiology

Science Blog

My Locations

My Education

MD: UT Southwestern, Dallas, TX, 1993.

Residency: Children's Hospital of Dallas, Dallas, TX, 1996.

Fellowship: The Children's Hospital, Denver, CO, 2002.

Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.

My Publications

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Jordan, MB; Allen, CE; Greenberg, J; Henry, M; Hermiston, ML; Kumar, A; Hines, M; Eckstein, O; Ladisch, S; Nichols, KE; et al. Pediatric Blood and Cancer. 2019; 66.

TNF-mediated compensatory immunity to mycobacterium avium in the absence of macrophage activation by IFN-γ. Resende, M; Cardoso, MS; Fróis-Martins, R; Borges, M; Jordan, MB; Castro, AG; Appelberg, R. Journal of immunology (Baltimore, Md. : 1950). 2019; 203:2451-2458.

Identifying and targeting pathogenic PI3K/AKT/ mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease. Fajgenbaum, DC; Langan, RA; Japp, AS; Partridge, HL; Pierson, SK; Singh, A; Arenas, DJ; Ruth, JR; Nabel, CS; Stone, K; et al. Journal of Clinical Investigation. 2019; 130:4451-4463.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. La Rosee, P; Horne, A; Hines, M; Greenwood, TV B; Machowicz, R; Berliner, N; Birndt, S; Gil-Herrera, J; Girschikofsky, M; Jordan, MB; et al. Blood. 2019; 133:2465-2477.

CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade. Garcia-Perez, JE; Baxter, RM; Kong, DS; Tobin, R; McCarter, M; Routes, JM; Verbsky, J; Jordan, MB; Dutmer, CM; Hsieh, EW Y. Frontiers in Immunology. 2019; 10.

Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Eckstein, OS; Visser, J; Rodriguez-Galindo, C; Allen, CE; Zinn, DJ; Peckham-Gregory, EC; Lin, H; Henry, MM; Morland, B; Levy, CF; et al. Blood. 2019; 133:1691-1694.

Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. Dorjbal, B; Stinson, JR; Ma, CA; Weinreich, MA; Miraghazadeh, B; Hartberger, JM; Frey-Jakobs, S; Weidinger, S; Moebus, L; Franke, A; et al. Journal of Allergy and Clinical Immunology. 2019; 143:1482-1495.

Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Lounder, DT; Bin, Q; De Min, C; Jordan, MB. Blood Advances. 2019; 3:47-50.

Gimap5-dependent inactivation of GSK3 beta is required for CD4(+) T cell homeostasis and prevention of immune pathology. Patterson, AR; Endale, M; Lampe, K; Aksoylar, HI; Flagg, A; Woodgett, JR; Hildeman, D; Jordan, MB; Singh, H; Kucuk, Z; et al. Nature Communications. 2018; 9.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65:e27400-e27400.